{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:10:29Z","timestamp":1790359829186,"version":"4.1.0"},"reference-count":118,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2019,10,3]]},"DOI":"10.1080\/14712598.2019.1665017","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T10:03:45Z","timestamp":1568282625000},"page":"1045-1056","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Rituximab biosimilars for lymphoma in Europe"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"first","affiliation":[{"name":"Oncology Centre, Maria Sk\u0142odowska-Curie Institute, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"D\u0142ugosz Danecka","sequence":"additional","affiliation":[{"name":"Oncology Centre, Maria Sk\u0142odowska-Curie Institute, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Ulm, Institute for Experimental Tumor Research, University Hospital Ulm, Ulm, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"CIT0001","unstructured":"European Medicines Agency. MabThera summary of product characteristics (SmPC) 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.2174\/1389201003379059"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.57"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00163"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw400"},{"key":"CIT0007","unstructured":"European Medicines Agency. Assessment Report: Rixathon 2017 [cited 2019 Jul 19]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003903\/WC500232462.pdf"},{"key":"CIT0008","unstructured":"European Medicines Agency. Assessment Report: Truxima 2016 [cited 2019 Jul 19]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/truxima-epar-public-assessment-report_en.pdf"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-016-0151-x"},{"key":"CIT0010","unstructured":"GaBI Online. Biosimilars approved in Europe 2011 [cited 2019 Jul 19]. Available from: http:\/\/www.gabionline.net\/Biosimilars\/General\/Biosimilars-approved-in-Europe"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30106-0"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000234"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1110"},{"issue":"6","key":"CIT0014","first-page":"676","volume":"2","author":"Boross P","year":"2012","journal-title":"Am J Cancer Res"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.146"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588376"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082412"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00447-7"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"issue":"1","key":"CIT0027","first-page":"486","volume":"130","author":"Salles GA","year":"2017","journal-title":"Blood"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.7926"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108415"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh093"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3911"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600926572"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556"},{"key":"CIT0041","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas 2019 [cited 2019 Jul 19]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"CIT0042","unstructured":"European Medicines Agency (EMA). Guideline on similar biological medicinal products containing monoclonal antibodies \u2013 non-clinical and clinical issues 2012 [cited 2019 Jul 19]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf"},{"key":"CIT0043","unstructured":"Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product 2015. [cited 2019 Jul 19]. Available from: https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm291128.pdf"},{"key":"CIT0044","volume-title":"1st Malaysia-Japan Symposium on Pharmaceutical Regulatory","author":"Kishioka Y","year":"2015"},{"key":"CIT0045","unstructured":"Therapeutic Goods Administration. Biosimilar medicines regulation. Version 2.2, April 2018. [cited 2019 Jul 19]. Available from: https:\/\/www.tga.gov.au\/publication\/biosimilar-medicines-regulation"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex278"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.2066"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3746"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.03.011"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.01.002"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.04.002"},{"key":"CIT0052","unstructured":"European Medicines Agency (EMA). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues 2014. [cited 2019 Jul 19]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.04.003"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.072"},{"key":"CIT0055","unstructured":"US Food and Drug Administration (FDA). Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics 2018 [cited 2019 Jul 19]. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071590.pdf"},{"key":"CIT0056","unstructured":"US Food and Drug Administration (FDA). Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry 2015 [cited 2019 Jul 19]. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf"},{"key":"CIT0057","unstructured":"US Food and Drug Administration (FDA). Considerations in demonstrating interchangeability with a reference product guidance for industry. DRAFT GUIDANCE 2017 [cited 2019 Jul 19]. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM537135.pdf"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4107"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp523"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.8651"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0036-3"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.843090"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209540"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0232-7"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0233-6"},{"key":"CIT0066","unstructured":"ClinicalTrials.gov. NCT01534949: provide initial evidence of safety, pharmacokinetics, pharmacodynamics, and efficacy to support the pivotal CT-P10 therapeutic equivalence trial (Triad-DLBCL) 2012 [cited 2019 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01534949"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1487912"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211281"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30157-1"},{"key":"CIT0070","unstructured":"ClinicalTrials.gov. NCT01933516: GP2013 in Japanese patients with CD20 positive low tumor burden indolent b-cell non-Hodgkin\u2019s lymphoma 2013 [cited 2019 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01933516"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30120-5"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23771"},{"key":"CIT0073","unstructured":"GaBI Online. Rituximab biosimilar submitted to EMA and Rituxan gains extra indication 2018. [cited 2019 Jul 19]. Available from: http:\/\/www.gabionline.net\/Biosimilars\/News\/Rituximab-biosimilar-submitted-to-EMA-and-Rituxan-gains-extra-indication"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313520351"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12916"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13094"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23586"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111248"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.e14020"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0171-8"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1633632"},{"key":"CIT0082","volume-title":"22nd Congress of European Hematology Association","author":"McBride H","year":"2017"},{"key":"CIT0083","unstructured":"ClinicalTrials.gov. NCT02747043. Study to assess if ABP798 is safe & effective in treating non Hodgkin lymphoma compared to rituximab (JASMINE) 2016 [cited 2019 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02747043"},{"key":"CIT0084","unstructured":"ClinicalTrials.gov. NCT02792699. Study to assess if ABP798 is safe & effective in treating moderate to severe rheumatoid arthritis compared to rituximab 2016 [cited 2019 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02792699"},{"key":"CIT0085","unstructured":"ClinicalTrials.gov. NCT02617485. MabionCD20\u00ae compared to MabThera\u00ae in lymphoma patients 2015 [cited 2019 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02617485"},{"key":"CIT0086","unstructured":"ClinicalTrials.gov. NCT02468791. MabionCD20\u00ae compared to MabThera\u00ae in patients with rheumatoid arthritis 2015 [cited 2019 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02468791"},{"key":"CIT0087","unstructured":"ClinicalTrials.gov. NCT02809053. A randomized, double-blind, multi-center, multi-national trial to evaluate the efficacy, safety, and immunogenicity of SAIT101 versus rituximab as a first-line immunotherapy treatment in patients with low tumor burden follicular lymphoma (RAMO-2) 2016 [cited 2019 Jul 19]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02809053"},{"key":"CIT0088","unstructured":"IQVIA Institute for Human Data Science. Global oncology trends 2019: therapeutics, clinical development and health system implications 2019 [cited 2019 Jul 19]. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/global-oncology-trends-2019.pdf"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw213"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.17925\/EOH.2017.13.02.114"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-000850"},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1638362"},{"issue":"4","key":"CIT0093","first-page":"3","volume":"7","author":"Mulcahy AW","year":"2018","journal-title":"Rand Health Q"},{"key":"CIT0094","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13552"},{"key":"CIT0095","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01070"},{"key":"CIT0096","doi-asserted-by":"publisher","DOI":"10.17925\/EOH.2017.13.02.102"},{"key":"CIT0097","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18743"},{"key":"CIT0098","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30374-6"},{"key":"CIT0099","unstructured":"Quintiles IMS. The impact of biosimilar competition in Europe 2017. [cited 2019 Jul 19]. Available from: https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2017\/05\/IMS-Biosimilar-2017_V9.pdf"},{"key":"CIT0100","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-011-0196-3"},{"issue":"5","key":"CIT0101","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/art.39568","volume":"68","author":"Kay J","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"CIT0102","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.110"},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.03.031"},{"key":"CIT0104","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1402996"},{"key":"CIT0105","doi-asserted-by":"publisher","DOI":"10.1080\/10826076.2013.794738"},{"key":"CIT0106","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3083-x"},{"key":"CIT0107","doi-asserted-by":"publisher","DOI":"10.4103\/injr.injr_98_17"},{"key":"CIT0108","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2980-4"},{"key":"CIT0109","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.125248"},{"key":"CIT0110","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_241_17"},{"key":"CIT0111","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-017-0885-x"},{"key":"CIT0112","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3332-8"},{"key":"CIT0113","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.5467.5467"},{"key":"CIT0114","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.1715"},{"key":"CIT0115","doi-asserted-by":"publisher","DOI":"10.3390\/ph7050530"},{"key":"CIT0116","unstructured":"World Health Organization (WHO). Economic crisis, health systems and health in Europe: country experience 2015 [cited 2019 Jul 19]. Available from: http:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0010\/279820\/Web-economic-crisis-health-systems-and-health-web.pdf?ua=1"},{"key":"CIT0117","unstructured":"IQVIA Institute for Human Data Science. Advancing biosimilar sustainability in Europe: a multi-stakeholder assessment 2018 [cited 2019 Jul 19]. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/advancing-biosimilar-sustainability-in-europe.pdf"},{"issue":"7","key":"CIT0118","first-page":"699","volume":"9","author":"Tinsley SM","year":"2018","journal-title":"J Adv Pract Oncol"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2019.1665017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T05:16:29Z","timestamp":1695186989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2019.1665017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":118,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,3]]}},"alternative-id":["10.1080\/14712598.2019.1665017"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2019.1665017","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}